Slide background
TAmiRNA – Triple A research and development of RNA diagnostics and therapeutics
Slide background
TAmiRNA – Introducing personalized medicine to Aging
Slide background
TAmiRNA – Harnessing the power of microRNAs for development of innovative diagnostic and therapeutic tools
Slide background
TAmiRNA – Helping to enhance your stability and quality of life with advanced age

microRNAs and platelet function

 

platelet function

Platelets play a key role in hemostasis, initiating and propagating thrombosis (1). Dysregulation and inappropriate activation of platelets occur in a wide range of serious age‑associated diseases, including stroke and myocardial infarction, whereas impairment of platelet functions results in bleeding disorders and bleeding risk during surgery.

Mature, anucleate platelets contain not only messenger RNA transcripts as well as the necessary machinery to conduct translation, but also microRNAs (miRNAs), which regulate translation of proteins (2). MicroRNA expression profiles within platelets strongly correlate with platelet function and reactivity.

During activation, platelets release microvesicles that contain microRNAs, which might be taken up by other cells and regulate the recipient cell´s mRNA profile and gene expression. Platelet-derived microRNAs (thrombomiRs) can be detected in cell-free blood, i.e. serum and plasma samples. The encapsulation in extracellular vesicles stabilizes microRNAs, allowing robust detection in frozen serum and plasma, even after storage for several years. The concentration of thrombomiRs in cell-free blood is known to decrease upon platelet inhibition or increase upon platelet activation. Therefore, the quantification of thrombomiRs is useful for the diagnosis of platelet-related disorders and for monitoring the pharmacologic effects of platelet inhibitors.

 

platelet function tests – gold-standard

Commonly used ex-vivo platelet function tests such as light transmission aggregometry (LTA), VerifyNow® or PFA-100®, require fresh blood and specific agonists that trigger platelet activation via one specific pathway. For this reason, they clearly lack standardization and their analytical variability may induce misinterpretations (3). Therefore, circulating microRNA, plasma and serum microRNA profiles may find use in clinical practice as novel biomarkers and markers of prognosis and treatment response.

 

clinical utility for microRNA biomarkers for platelet function

Platelet microRNAs are a novel and complementary measure of platelet function, because

  • they are indicative of the overall reactivity of platelets, independent of a specific activation pathway
  • they are generated by platelets in vivo, and therefore are considered the most appropriate surrogate biomarker of in-vivo platelet function (4)
  • they can be used to analyze platelet function retrospectively, by using deep-frozen serum or plasma samples

Overall, this simplifies the assessment of platelet function, which is important for determining the platelet status of a patient to assess the bleeding risk and response to therapeutic platelet inhibition.

measurability

Circulating microRNAs can be quantified in serum as well as plasma samples using quantitative PCR. This gold-standard method is reliable and can undergo technical validation. However, in order to be successful, a well-characterized and standardized protocol must be used. TAmiRNA has developed a robust workflow and offers qPCR Kits together with software solutions for circulating microRNA analysis.

validated biology

Numerous studies have by now validated the regulation of thrombomiRs (and therefore platelet reactivity) in patients with acute coronary syndrome, type-2 diabetes and after anti-platelet therapy. In the following a few examples for so-called “thrombomiRs” are given:

  • miR-223-3p is highly enriched in mature platelets where it regulates for example expression (4)
  • Serum and plasma levels of miR-223-3p significantly decline during anti-platelet therapy in a dose-dependent fashion. Similar observations were made for miR-126-3p, miR-197-5p, miR-24-3p and miR-21-5p (4)
  • miRNA-197 and miRNA-223 predict cardiovascular death in a cohort of patients with symptomatic coronary artery disease
  • miR-126-3p and miR-320a were decreased in plasma in prevalent type 2 diabetes using samples of the prospective population-based Bruneck study (5)
  • miR-27b-3p and miR-320a play a role in risk estimation of microvascular complications in patients with type-1 diabetes (5, 6)
  • miR-150-5p and miR-191-5p were decreased after platelet inhibition (4)

decision support

The thrombomiRTM kit allows users to analyze 10 distinct platelet-derived microRNAs with specific biological functions and clinical utility. Therefore, the thrombomiR™ test reports a novel measure of in-vivo platelet function, that is independent of a specific activation pathway. The thrombomiR software simplifies the analysis and interpretation of qPCR data.

 

further reading

  1. Sunderland N, et al. MicroRNA Biomarkers and Platelet Reactivity: The Clot Thickens. Circ. Res. 2017.
  2. Landry P, Plante I, et al. Existence of a microRNA pathway in anucleate platelets. Nature Structural &Molecular Biology. 2009 Nature Publishing Group, 16(9), pp. 961–966.
  3. Paniccia R, Priora R, Liotta A. and Abbate R. Platelet Function tests: A Comparative Review. Vascular Health and Risk Management. 2015;11, pp. 133–148.
  4. Willeit P, Zampetaki A, Dudek K, Kaudewitz D, et al. Circulating microRNAs as novel biomarkers for platelet activation. Circ Res. 2013 Feb 15;112(4):595-600.
  5. Zampetaki A, Kiechl S, Drozdov I, et al. Plasma microRNA profiling reveals loss of endothelial miR-126 and other microRNAs in type 2 diabetes. Circ Res. 2010 Sep 17;107(6):810-7.
  6. Zampetaki A, Willeit P, Burr S, et al. Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes. Diabetes 2015 65(1), pp. 216–27.
  7. A, Røsjø H, Nauman J, et al. Circulating microRNAs predict future fatal myocardial infarction in healthy individuals - The HUNT study. J Mol Cell Cardiol. 2016;97:162-8.
  8. Kaudewitz D, Skroblin P, Bender LH, Barwari T, et al. Association of MicroRNAs and YRNAs with Platelet Function. Circ Res. 2016 Feb 5;118(3):420-32.
  9. Mayr M, Zampetaki A, Willeit P, Willeit J, Kiechl S. MicroRNAs within the continuum of postgenomics biomarker discovery. Arterioscler Thromb Vasc Biol. 2013 Feb;33(2):206-14.
  10. Zampetaki A, Willeit P, Tilling L, Drozdov I, et al. Prospective study on circulating MicroRNAs and risk of myocardial infarction. J Am Coll Cardiol. 2012 Jul 24;60(4):290-9.

 
 

Click here for your personalized microRNA service offer!